Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

Abstract Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Even with a high disease control rate, a majority of patients develop acquired EGFR-TKIs r...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Di Hu, Yan-Yan Zhou, Hong-Bo Ma, Miao-Miao Tao, Qun-Zhen Huang, Zhen-Zhou Yang, Qi Zhou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-06-01
Edice:	BMC Pulmonary Medicine
Témata:	NSCLC EGFR mutation EGFR-TKIs Angiogenesis inhibitors Meta-analysis
On-line přístup:	https://doi.org/10.1186/s12890-023-02472-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!